• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "April, 2021"
 Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt
 0
By Nascent Biotech
In Press Releases
Posted April 26, 2021

Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt

SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.